Chemoprevention

Program researchers are investigating the use of chemotherapeutic agents in the prevention of prostate and breast cancer. NCI-sponsored prostate prevention trials at Stanford include the Prostate Cancer Prevention Trial (PCPT) and the Selenium and Vitamin E Chemoprevention Trial (SELECT). These randomized Stanford trials involve 372 patients and 70 patients, respectively.

Researchers are also conducting an investigator-initiated clinical trial of lovastatin in BRCA1/2 carriers or other women at high inherited risk for breast cancer. The goal of this study is to assess whether oral lovastatin, given daily at a dose of 80 mg for six months, results in a 25% decrease in the rate of abnormal breast duct cytology among study participants